4 unknown, 2 completed, 2 recruiting, 1 active not recruiting. 10 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 10 | Unknown 4, Completed 2, Recruiting 2, Active not recruiting 1, Not yet recruiting 1 |
Follow Dasatinib: new trials by email Literature Review of Dasatinib trials Research Report on Dasatinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bioequivalence Studies of Dasatinib 100 Mg Dasatinib 100 MG - Myeloma Multiple | Phase 4 | Not yet recruiting | Centro de Atencion e Investigacion Medica | 46 | 2025-09-01 | 2025-02-12 |
| Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma Foresight CEP + Dasatinib + Azacitidine - Angioimmunoblastic T-cell Lymphoma (AITL) | Phase 4 | Active not recruiting | Zhengzhou University | 34 | 2023-10-21 | 2025-07-01 |
| Asciminib Roll-over Study Asciminib single agent, Imatinib, Nilotinib - Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Phase 4 | Recruiting | Novartis Pharmaceuticals | 347 | 2022-08-30 | 2026-11-09 |
| The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients Flumatinib, Dasatinib - Chronic Myeloid Leukemia in Chronic Phase | Phase 4 | Unknown | Shenzhen Second People's Hospital | 118 | 2021-07-01 | 2022-07-27 |
| Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP Dasatinib - Dasatinib, BCR-ABL | Phase 4 | Unknown | Shenzhen Second People's Hospital | 65 | 2019-12-01 | 2022-07-27 |
| A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Dasatinib Tablets - Chronic Myelogenous Leukemia - Chronic Phase | Phase 4 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 62 | 2016-05-10 | 2021-06-14 |
| Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia Dasatinib 50 MG - Chronic Myelogenous Leukemia | Phase 4 | Unknown | Hospital Universitario Dr. Jose E. Gonzalez | 12 | 2016-04-01 | 2017-07-13 |
| Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients Dasatinib, prednisone, dexamethasone - ph+ Acute Lymphoblastic Leukemia | Phase 4 | Unknown | Tongji Hospital | 40 | 2016-03-01 | 2016-02-24 |
| Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease Bortezomib, Eltrombopag, Imatinib - Hematological Neoplasms | Phase 4 | Recruiting | Wei Zhao | 1500 | 2016-01-31 | 2025-03-30 |
| Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib Dasatinib - Chronic Phase Chronic Myeloid Leukemia | Phase 4 | Completed | Bristol-Myers Squibb | 39 | 2012-12-01 | 2016-11-22 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (3) · Leukemia, Myeloid, Chronic-Phase (2) · Blast Crisis (1) · Hematologic Neoplasms (1) · Immunoblastic Lymphadenopathy (1) · Multiple Myeloma (1) · Myeloproliferative Disorders (1)
Shenzhen Second People's Hospital (2) · Bristol-Myers Squibb (1) · Centro de Atencion e Investigacion Medica (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Hospital Universitario Dr. Jose E. Gonzalez (1) · Novartis Pharmaceuticals (1) · Tongji Hospital (1) · Wei Zhao (1) · Zhengzhou University (1)
China (7) · France (2) · Germany (2) · Italy (2) · Mexico (2) · South Korea (2) · United States (2) · Argentina (1) · Austria (1) · Brazil (1) · Bulgaria (1) · Canada (1) · Colombia (1) · Czechia (1) · Denmark (1)
Li Meng, professor (1) · Wei Zhao, Ph.D (1)
PMID 24357015, PMID 34240339, PMID 38497347, PMID 38616308
2023 (1)